Cullinan Oncology to Provide Clinical Update for CLN-081 in NSCLC EGFR Exon 20 Patients

Rhea-AI Summary

Cullinan Oncology (Nasdaq: CGEM) will host a clinical update webinar on December 16, 2021, at 8:00 AM ET, focusing on its investigational drug CLN-081. This oral EGFR inhibitor targets non-small cell lung cancer patients with specific mutations. The webinar will present updated safety and efficacy data from a Phase 1/2a trial for patients whose disease has progressed after previous therapies. Interested participants can register via the company's investor website, with an archived recording available for 30 days post-webinar.

Positive

• CLN-081 shows potential as a targeted therapy for NSCLC with EGFR exon 20 mutations.
• The ongoing Phase 1/2a trial could provide valuable efficacy and safety data, possibly leading to advancements in treatment options.

Negative

• None.

CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology therapies, will provide a clinical update on CLN-081 during a webinar on Thursday, December 16, 2021, at 8:00 a.m. ET.

During the webinar, Cullinan’s team will review updated safety and efficacy data from an ongoing Phase 1/2a trial evaluating CLN-081 in non-small cell lung cancer (NSCLC) patients harboring Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations whose disease has progressed on or after prior therapy.

CLN-081 Clinical Update Webinar Information

Participants can register for the webinar through the events section on Cullinan’s investor website. An archived recording of the live audio webcast will be available on Cullinan’s website for approximately 30 days.

About CLN-081

CLN-081 is an orally available, irreversible EGFR inhibitor that selectively targets cells expressing EGFR exon 20 insertion mutations while sparing cells expressing wild type EGFR. Cullinan is evaluating various doses of CLN-081 in a Phase 1/2a trial in patients with NSCLC harboring exon 20 mutations whose disease has progressed on or after prior therapy.

About Cullinan Oncology

Cullinan Oncology is a biopharmaceutical company that is developing a diversified pipeline of targeted therapeutic candidates across multiple modalities in order to bring important medicines to cancer patients. The Company’s strategy is to source innovation through both internal discovery efforts and external collaborations, focusing on advanced stage assets with novel technology platforms and differentiated mechanisms. Learn more about Cullinan at www.cullinanoncology.com.

Contacts:

Jeffrey Trigilio
+1 617.410.4650
jtrigilio@cullinanoncology.com

Investor Relations
Lee Roth / Dr. Grace Kim
+1 212.213.0006
lroth@burnsmc.com / gkim@burnsmc.com

Media
Ariane Lovell
+1 917.565.2204
ariane.lovell@finnpartners.com

FAQ

What is the purpose of the upcoming Cullinan Oncology webinar on December 16, 2021?

The webinar will provide a clinical update on CLN-081, focusing on safety and efficacy data from an ongoing Phase 1/2a trial.

What does CLN-081 target?

CLN-081 is an irreversible EGFR inhibitor designed to target non-small cell lung cancer patients with EGFR exon 20 insertion mutations.

How can I register for the CLN-081 clinical update webinar?

Participants can register through the events section on Cullinan Oncology's investor website.

What is the expected outcome of the Phase 1/2a trial for CLN-081?

The trial aims to evaluate the safety and efficacy of CLN-081 in patients with NSCLC whose disease has progressed on prior therapy.